High-flow cannula for frail patients with SARS-CoV-2 infection non-eligible for intensive care unit management - 05/03/23
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | High flow nasal cannula implementation in conventional units for elder and frailest patients was easy. |
• | The survival rate was 25 % in those old and critically ill patients. |
• | The main factor associated with survival was a lower Charlson Comorbidity index. |
Abstract |
Objectives |
High-flow nasal cannula (HFNC) was widely used during the COVID-19 pandemic in intensive care units (ICU), but there is no recommendation for elderly patients non-eligible for ICU management. We aimed to describe the outcomes of HFNC treatment in patients with COVID-19 who are not eligible for ICU management.
Methods |
Retrospective bicentric cohort study performed between September 1, 2020 and June 30, 2021 in two infectious diseases departments of Colmar Hospital and Antoine Beclere University Hospital, France.
Results |
Sixty-four patients were treated with HFNC: 33 in Colmar and 31 in Beclere hospital (median age: 85 years; IQ, 82–92). Of these, 16 patients survived (25%). Surviving patients had a lower Charlson comorbidity index score than deceased patients (five vs six; p = 0.02).
Conclusions |
Despite a high death rate, with survivors being younger and having fewer comorbidities, HFNC is an easy tool to implement in non-ICU wards for the frailest patients.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, High-flow oxygen, High-flow nasal cannula, Elderly, Tocilizumab
Plan
| ☆ | Presented at the 2021 RICAI, Paris. |
Vol 53 - N° 2
Article 104635- mars 2023 Retour au numéro
Article précédent
- A single dose of ciprofloxacin reduces the duration of diarrhea among service members deployed in Africa
- E. Le Dault, S. Sicard, J. Desplans, A. Mayet, F. Simon, L. Aigle, H. Savini, T. Coton, C. Marimoutou, TAMIDOPEX team
- Suboptimal exposure to fluconazole in critically ill patients: Pharmacokinetic analysis and determinants
- A.L. Bienvenu, P. Pradat, E. Matusik, V. Piriou, T. Rimmelé, F. Parant, M. Tod, G. Leboucher, S. Goutelle, Antifungal study group, Florence Ader, Laurent Argaud, Frédéric Aubrun, Jean-Luc Fellahi, Céline Guichon, Laurent Juillard, Vincent Leclerc, Charline Miossec, Carole Paillet, Alexandra Plesa, Jean-Christophe Richard, Sandrine Roux, Florent Wallet
Bienvenue sur EM-consulte, la référence des professionnels de santé.